Well-Funded Denali Adds CMO Carole Ho, Another Genentech Alum

Xconomy San Francisco — 

Denali Therapeutics has named Carole Ho as its chief medical officer and head of development. Ho becomes the latest ex-Genentech executive to join the neuroscience startup, which launched in May with $217 million in backing.

Ho, who was previously vice president of early clinical development at Genentech, joins at least three other alums at Denali, which aims to develop therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Denali CEO Ryan Watts was Genentech’s director of neuroscience; COO Alex Schuth was Genentech’s top neuroscience dealmaker; and chairman Marc  Tessier-Lavigne was Genentech’s chief scientific officer before taking over as president of Rockefeller University in New York in 2011.